公开(公告)号：EP0162043A1

公开(公告)日：1985-11-27

申请号：EP84900064.0

申请日：1983-12-20

申请人： BRU, Jean

发明人： BRU, Jean

IPC分类号： A61J3 ,  A61K9 ,  B01J2

CPC分类号： A61K9/0007 ,  B01J2/16 ,  Y10S514/96 ,  Y10S514/961

摘要： Le procédé de fabrication de granulés effervescents consiste en les étapes d'humidification ménagée du mélange acide + base, de préséchage puis de séchage final et de granulation. On a découvert que ces opérations peuvent être réalisées dans un seul appareil, soit intégralement en lit fluidisé, soit avec séchage par le vide, dans une tour de fabrication (1) comprenant un appareil de mélange-granulation-séchage sous vide (4). Homogénéité beaucoup plus grande.

公开(公告)号：EP1913945A3

公开(公告)日：2008-04-30

申请号：EP07120386.3

申请日：2000-11-16

申请人： SMITHKLINE BEECHAM PLC

发明人： Lewis, Karen ,  Lilliott, Nicola, Jayne ,  Mackenzie, Donald, Colin

IPC分类号： A61K31/425 ,  A61K9/20 ,  A61K9/50 ,  A61K31/155 ,  A61P3/10

CPC分类号： A61K31/425 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/5084 ,  A61K31/155 ,  A61K31/427 ,  A61K31/4439 ,  Y10S514/866 ,  Y10S514/96 ,  Y10S514/961 ,  Y10S514/962 ,  A61K2300/00

摘要： A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition for use in the treatment of conditions associated with the pre-diabetic state.

公开(公告)号：EP0871435B1

公开(公告)日：2006-11-22

申请号：EP96904590.5

申请日：1996-02-08

申请人： Duramed Pharmaceuticals Inc.

发明人： PINNAMARAJU, Prasad ,  ZHANG, Guohua

IPC分类号： A61K9/22

CPC分类号： A61K9/2031 ,  A61K9/2027 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/277 ,  Y10S514/96 ,  Y10S514/961

摘要： Verapamil depot drug formulations include the pharmaceutical itself and a three component release rate controlling matrix composition. The three components of the matrix composition are (1) an alginate component, such as sodium alginate, (2) an enteric polymer component, such as methacrylic acid copolymer, and (3) a pH independent gelling polymer, such as hydroxypropyl methylcellulose or polyethyleneoxide. The drug release rate can be adjusted by changing the amount of one or more of these components of the composition.

公开(公告)号：EP1656126A1

公开(公告)日：2006-05-17

申请号：EP04773926.3

申请日：2004-06-15

申请人： Kyungdong Pharm. Co., Ltd.

发明人： LEE, Byoung-Suk ,  LEE, Ah-Ram ,  PARK, Jong-Sik ,  KIM, Eun-Ju ,  GIL, Hyung-Joon

IPC分类号： A61K31/18 ,  A61K31/137 ,  A61K47/14

CPC分类号： A61K9/2018 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2095 ,  A61K31/137 ,  A61K31/18 ,  Y10S514/96 ,  Y10S514/961 ,  Y10S514/964

摘要： The present invention relates to a simple and effective method for preparing a tamsulosin HCl sustained-release tablet and a tamsulosin HCl sustained-release tablet produced thereby. The method comprises the steps of: dissolving tamsulosin HCl as an active ingredient in an organic solvent; dissolving the tamsulosin HCl solution in hydroxypropylmethylcellulose phthalate to prepare a binder solution; and kneading the binder solution with a hydroxypropylmethylcellulose phthalate/glyceryl dibehenate mixture as an excipient and allows tamsulosin HCI to be released at uniformly controlled amounts in a subtained-release manner in vivo by controlling drug release rate according to different pH environments in vivo, so that it shows improved bioavailability and minimized side effects.

公开(公告)号：EP1231918B1

公开(公告)日：2005-04-06

申请号：EP00976156.0

申请日：2000-11-16

申请人： SmithKline Beecham plc

发明人： LEWIS, Karen SmithKline Beecham Pharmaceuticals ,  LILLIOTT, Nicola Jayne SmithKline Beecham Pharmac. ,  MACKENZIE, Donald C. SmithKline Beecham Pharmaceu.

IPC分类号： A61K31/425 ,  A61K9/20 ,  A61K9/50 ,  A61K31/155 ,  A61P3/10

CPC分类号： A61K31/425 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/5084 ,  A61K31/155 ,  A61K31/427 ,  A61K31/4439 ,  Y10S514/866 ,  Y10S514/96 ,  Y10S514/961 ,  Y10S514/962 ,  A61K2300/00

摘要： A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.

公开(公告)号：EP1166651A1

公开(公告)日：2002-01-02

申请号：EP01123407.7

申请日：1997-02-21

申请人： FUJISAWA PHARMACEUTICAL CO., LTD.

发明人： Yamaguchi, Hisami

IPC分类号： A23L1/236 ,  A61K31/545 ,  A61K9/20 ,  A61K47/38 ,  A61K47/30

CPC分类号： A61K31/546 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/545 ,  Y10S514/96 ,  Y10S514/961

摘要： This invention provides synthetic sweeteners which are suitable for masking a bitter taste in pharmaceutical preparations.
The synthetic sweetener is selected from the group consisting of saccharin or a salt thereof and cyclamic acid or a salt thereof. The synthetic sweetener has a mean particle size of not less than 150 µm and is produced by wet or dry granulation.
The invention further provides granulated synthetic sweeteners comprising the synthetic sweetener and light anhydrous silicic acid and/or hydrated silicon dioxide.

摘要翻译： 本发明提供了合成甜味剂，其适合用于掩蔽在药物制剂苦味。 合成甜味剂是选自糖精或其盐和环己烷氨基磺酸或其盐组成的组。 合成甜味剂具有不小于150微米的平均粒度和通过湿法或干法造粒制备。 本发明提供了进一步的造粒合成甜味剂包括合成甜味剂和轻度无水硅酸和/或水合二氧化硅。

公开(公告)号：EP1162973A1

公开(公告)日：2001-12-19

申请号：EP00909776.7

申请日：2000-03-21

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： MUKAI, Tadashi ,  TOMOHIRA, Yuso ,  TODA, Masafumi ,  YAMADA, Keigo ,  OKA, Yoshikazu

IPC分类号： A61K31/47 ,  A61K9/14

CPC分类号： A61K9/145 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/2081 ,  A61K9/5042 ,  A61K9/5084 ,  A61K31/4709 ,  Y10S514/951 ,  Y10S514/952 ,  Y10S514/96 ,  Y10S514/961 ,  Y10S514/962 ,  Y10S514/963 ,  Y10S514/964

摘要： Provided is a cilostazol preparation which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.

公开(公告)号：EP1066836A1

公开(公告)日：2001-01-10

申请号：EP99201865.5

申请日：1999-06-11

申请人： Sensus, part of Coöperatie COSUN U.A.

发明人： The designation of the inventor has not yet been filed

IPC分类号： A61K47/36

CPC分类号： A61K47/36 ,  Y10S514/951 ,  Y10S514/961

摘要： The invention relates to a novel filler-binder for tablets, which shows a significantly reduced lubricant sensitivity when compared to prior art filler-binders. The invention further relates to a process of making said filler-binder and to the tablet obtainable by said process.

摘要翻译： 本发明涉及一种新的片剂填料 - 粘合剂，与现有技术的填料 - 粘合剂相比，其显示出显着降低的润滑剂敏感性。 本发明还涉及通过所述方法制备所述填料 - 粘合剂和片剂的方法。

公开(公告)号：EP0950419A1

公开(公告)日：1999-10-20

申请号：EP99106935.2

申请日：1999-04-08

申请人： Shin-Etsu Chemical Company, Ltd.

发明人： Tanno, Fumie c/o Specialty Chemicals Research ,  Kokubo, Hiroyasu, c/o Specialty Chemicals Research

IPC分类号： A61K47/38

CPC分类号： A61K9/2054 ,  Y10S514/961

摘要： A solid preparation characteristically containing for a binder methyl cellulose whose MeO content is 27.5-31.5 wt% and whose 2 wt% aqueous solution has a viscosity of 2-12 cP at 20°C.
The present invention can provide a solid preparation which has an adequate hardness and at the same time disintegrates quickly for easy absorption.

摘要翻译： 一种固体制剂，其特征在于，其含有MeO含量为27.5〜31.5重量％的粘合剂甲基纤维素，其20重量％的水溶液在20℃下的粘度为2-12cP。本发明可提供一种固体制剂，其具有 足够的硬度，同时快速分解，便于吸收。

公开(公告)号：EP0890359A4

公开(公告)日：1999-01-13

申请号：EP97904616

申请日：1997-02-21

IPC分类号： A23L27/30 ,  A61K20060101 ,  A61K9/00 ,  A61K9/20 ,  A61K31/545 ,  A61K31/546 ,  A61K47/30 ,  A61K47/38

CPC分类号： A61K31/546 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/545 ,  Y10S514/96 ,  Y10S514/961

摘要： Tablets containing a β-lactam antibiotic which can be easily taken as such because they are small and which, for administration to a dysphagic person, e.g., one of an advanced age, can be taken as a dispersion because they readily disintegrate by themselves when dropped into water in a glass. Each tablet comprises 60 to 85 wt.% β-lactam antibiotic, 1 to 10 wt.% lowly substituted hydroxypropylcellulose and/or crosslinked polyvinylpyrrolidone as a disintegrator, and 0.5 to 2 wt.% binder. For producing the tablets, these ingredients are tableted using water or an aqueous solution of ethanol, etc.

摘要翻译： 含有β-内酰胺抗生素的片剂可以容易地服用，因为它们很小，并且对于给予吞咽困难的人，例如高龄中的一种，可以作为分散剂，因为它们在滴下时容易自行崩解 放入玻璃水中。 每片包含60至85重量％的β-内酰胺抗生素，1至10重量％的低取代羟丙基纤维素和/或交联的聚乙烯吡咯烷酮作为崩解剂，以及0.5至2重量％的粘合剂。 为了生产片剂，将这些成分用水或乙醇水溶液等制成片剂